8 Contradicted by research
In a study of healthy young men restricted to 4 hours of sleep per night for 2 weeks, participants gained 11% visceral fat without gaining weight on the scale.
"These men were only sleeping four hours a night for two weeks. Okay, these are healthy young men, college-age students, young. They gained 11% visceral fat after that two weeks, but not a pound on the scale, but they had 11% higher visceral fat after just, you know, two weeks of not getting enough sleep." (said at 0:14:50)
The speaker is referring to a randomized crossover trial led by Covassin et al. (PMID 35361348) at the Mayo Clinic, in which 12 healthy non-obese participants (9 men, 3 women, aged 19–39) underwent 14 days of sleep restriction (4-hour sleep opportunity per night). The study did observe an approximate 11% increase in visceral abdominal fat (P = 0.042) alongside increased caloric intake. However, the speaker's claim that participants gained 'not a pound on the scale' is contradicted by the study findings: participants gained a statistically significant amount of weight during the sleep restriction condition compared to control sleep (~0.5 kg / 1.1 lbs, P = 0.008).
Resistance training and lifting weights do not significantly reduce visceral fat, whereas vigorous aerobic exercise such as running, cycling, or swimming does.
"So what I mean is resistance training and lifting weights don't really move the needle in terms of helping you lose visceral fat... But if you want to lose visceral fat, you're going to have to do running, jogging, cycling, swimming." (said at 0:24:41)
Multiple systematic reviews and meta-analyses of randomized controlled trials demonstrate that resistance training alone produces statistically significant reductions in visceral adipose tissue (VAT), directly contradicting the claim that lifting weights 'doesn't move the needle' for visceral fat loss. While vigorous aerobic exercise and high-intensity interval training (HIIT) generally demonstrate greater relative efficacy than resistance training in head-to-head network comparisons, aerobic exercise is not strictly required to achieve significant visceral fat reduction.
- contradicts: Effect of resistance training with and without caloric restriction on visceral fat: A syst… (Obesity reviews : an official journal of the International Association for the Study of Obesity 2021) · cited 54x in the literature
"Thirty-four studies including 38 intervention arms and involving 2285 were included in the meta-analysis. RT effectively reduced VF [-24 (95% CI -0.34 to -0.13), p < 0.001; I 2 = 4.17%, p = 0.40; 24 intervention arms] when compared with control... Our results confirm that RT may be effective for reducing VF" (abstract, results)
pubmedfull study (doi) - contradicts: The Effect of Resistance Training in Healthy Adults on Body Fat Percentage, Fat Mass and V… (Sports medicine (Auckland, N.Z.) 2022) · cited 123x in the literature
"Compared to the control, resistance training reduced body fat percentage by - 1.46% (95% confidence interval - 1.78 to - 1.14, p < 0.0001), body fat mass by - 0.55 kg (95% confidence interval - 0.75 to - 0.34, p < 0.0001) and visceral fat by a standardised mean difference of - 0.49 (95% confidence interval - 0.87 to - 0.11, p = 0.0114)... Resistance training reduces body fat percentage, body fat mass and visceral fat in healthy adults." (abstract, results)
pubmedfull study (doi) - partial: Effects of various exercise types on visceral adipose tissue in individuals with overweigh… (Obesity reviews : an official journal of the International Association for the Study of Obesity 2024) · cited 90x in the literature
"A total of 84 RCTs (4836 patients) were included. Aerobic exercise (AE) of at least moderate intensity, resistance training (RT), AE + RT, and high-intensity interval training (HIIT) were beneficial for reducing VAT... Surface under the cumulative ranking curve (SUCRA) probability ranking showed that AE with vigorous intensity and HIIT have the highest probability of being the best exercise intervention for improving VAT... and RT is the least effective intervention." (abstract, results)
pubmedfull study (doi)
Obesity accelerates ovarian aging and leads to earlier menopause.
"Obesity accelerates ovarian aging. So you're more likely to go into menopause earlier with obesity." (said at 0:36:27)
Large prospective cohort studies and meta-analyses consistently demonstrate that higher body mass index (overweight and obesity) is associated with a later age at natural menopause (or a lower risk of early natural menopause), rather than an earlier menopause. In contrast, being underweight is associated with an increased risk of early menopause. This is thought to be mediated in part by the peripheral conversion of androgens to estrogens in adipose tissue.
- contradicts: Adult adiposity and risk of early menopause. (Human reproduction (Oxford, England) 2017) · cited 59x in the literature
"Compared to women with BMI = 18.5-22.4 kg/m2, those with BMI < 18.5 kg/m2 had a significant 30% higher odds of early menopause (95% confidence interval (CI) = 1.08, 1.57), while women with BMIs between 25.0-29.9 kg/m2 had significant 21-30% lower odds. Odds were not higher in women with BMI ≥ 35.0 kg/m2 in fully adjusted analysis." (abstract, results)
pubmedfull study (doi) - contradicts: The association of adolescent to midlife weight change with age at natural menopause: a po… (American journal of epidemiology 2025) · cited 2x in the literature
"Conversely, women with the largest estimated weight gain had a lower hazard of reaching menopause (adjusted HR = 0.96; 95% CI, 0.93-0.99). Women with estimated stable high weight had the lowest hazard of reaching menopause (adjusted HR = 0.93; 95% CI, 0.90-0.95)." (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: Menopause Across Asia: A Comprehensive Meta-analysis of Age and Influencing Factors. (Journal of mid-life health 2025) · cited 3x in the literature
"Higher BMI, socioeconomic status, parity, and education were associated with delayedmenopause, whereas smoking, alcohol use, stressful and physically demanding workload, and early menarche were linked with earlier onset." (abstract, results, passage verified)
pubmedfull study (doi)
Approximately 20% of male infants are born with an undescended testicle.
"Something like 20% of boys now have an undescended testicle. I mean, it's crazy." (said at 0:46:38)
Epidemiological data and systematic reviews demonstrate that the true prevalence of undescended testes (cryptorchidism) at birth is approximately 1.0% to 4.6% (and up to 9% in some prospective cohorts) in term newborn boys, far below the claimed 20%. While premature or low birth weight infants (<2.5 kg) can have significantly higher rates of cryptorchidism due to incomplete testicular descent before 35 weeks of gestation, spontaneous descent typically occurs in the first months of life, reducing the overall prevalence to approximately 1.0% to 1.5% by age one.
Non-liposomal oral glutathione is not effectively absorbed or transported into human cells because cells lack transporters for external glutathione.
"The problem is because our body makes it inside of our cells, we don't have a transporter to get glutathione from the outside of our cells, like if we eat it and if it makes it through our digestion, which it really doesn't, into our cells. And so this kind of glutathione isn't going to make it inside of your cells." (said at 1:09:43)
The speaker claimed that non-liposomal oral glutathione cannot make it through digestion or enter human cells because cells completely lack transporters to import extracellular glutathione. This is contradicted by both clinical trial data and in vitro cellular uptake studies. In a randomized, double-blind, placebo-controlled trial in healthy adults (PMID 24791752), daily oral supplementation with plain glutathione significantly increased intracellular glutathione stores across multiple cell types (including erythrocytes, lymphocytes, and buccal cells) by 30% to 260% in a dose- and time-dependent manner. Additionally, comparative cellular uptake assays show that while liposomal formulations enhance uptake, plain non-liposomal glutathione is still taken up intracellularly (e.g., ~23% uptake in HEK 293T cells; PMID 41559937). Although intact oral glutathione has lower bioavailability and undergoes degradation into its constituent amino acids (which are then transported and resynthesized into intracellular GSH) alongside direct transport mechanisms, the blanket assertion that it 'isn't going to make it inside of your cells' due to a total absence of cellular uptake/transport is contradicted.
Old mice administered urolithin A showed tissue rejuvenation and a 20% lifespan extension.
"old mice that were given urolithin A were able to rejuvenate tissues, but also a 20% life extension was found in these mice given urolithin A. 20% is pretty big for a mouse study." (said at 1:35:55)
The speaker confuses findings in C. elegans (roundworms) with findings in mice. In the seminal 2016 Nature Medicine study by Ryu et al. (PMID: 27400265), urolithin A treatment extended lifespan by ~45% in C. elegans, while in mice and rats, it improved exercise capacity, muscle function, and tissue markers (healthspan/rejuvenation parameters), but lifespan extension was not demonstrated or reported in the mice.
Beta-hydroxybutyrate increases brain GABA levels, elevates BDNF, and reduces cellular oxidation.
"I have that beta-hydroxybutyrate which is increasing GABA, that inhibitory neurotransmitter that's silencing down some of the anxiety in the back of the brain or the chatter and just helping me focus. And also it increases brain-derived neurotrophic factor. So beta-hydroxybutyrate is a signaling molecule. It's able to increase brain-derived neurotrophic factor in the brain that helps with learning, memory, brain aging. It's also been shown to lower oxidation." (said at 1:44:50)
The speaker bundles three claims regarding beta-hydroxybutyrate (BHB): that it increases brain GABA, elevates brain-derived neurotrophic factor (BDNF), and reduces oxidation. In vivo human neuroimaging directly contradicts the GABA assertion: 7T proton magnetic resonance spectroscopy demonstrated that acute administration of D-BHB significantly decreased (downregulated) rather than increased cortical GABA and glutamate levels in healthy adults. Furthermore, randomized controlled trials of exogenous BHB supplementation in humans and rodents failed to detect increases in BDNF levels, although ketogenic diets elevate circulating BDNF in some contexts. Antioxidant effects of BHB have primarily been observed in preclinical and cellular models. Because the primary neurochemical mechanism (increasing GABA) is inverted relative to human experimental data, the claim is contradicted.
- contradicts: Acute administration of ketone beta-hydroxybutyrate downregulates 7T proton magnetic reson… (Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2023) · cited 31x in the literature
"Results show that levels of GABA and Glu were significantly reduced in the anterior and posterior cortices after administration of D-βHB. Importantly, the effect was specific to D-βHB and not observed after administration of glucose." (abstract, results)
pubmedfull study (doi) - contradicts: Effect of exogenous β-hydroxybutyrate on BDNF signaling, cognition, and amyloid prec… (American journal of physiology. Cell physiology 2025) · cited 4x in the literature
"There were no effects of ketone supplementation on plasma BDNF or cognition. Second, we aimed to investigate the mechanistic effects of acute and chronic β-OHB supplementation on cortical BDNF content and recognition memory in C57BL/6J mice with and without insulin resistance. Acutely, β-OHB did not alter recognition memory or BDNF content. Similarly, chronic β-OHB supplementation did not alter recognition memory or BDNF content. Collectively, our data demonstrates that ketone supplementation does not elevate BDNF content in humans or mice." (abstract, results)
pubmedfull study (doi) - partial: A 3-Week Ketogenic Diet Increases Global Cerebral Blood Flow and Brain-Derived Neurotrophi… (The Journal of clinical endocrinology and metabolism 2025) · cited 6x in the literature
"A KD led to increased basal plasma β-OHB levels compared to the SDD (647 [418-724] vs 50 [50-60] μmol/L, P < .05), increased CBF by 22% (P = .02), and elevated BDNF levels by 47% (P = .04)." (abstract, results)
pubmedfull study (doi)
Studies show that London taxi drivers do not get Alzheimer's disease.
"there's studies out there showing that these these types of um taxi drivers like do not get Alzheimer's disease." (said at 2:04:17)
Studies do not show that London taxi drivers are immune to Alzheimer's disease. While landmark neuroimaging research on London taxi drivers demonstrated hippocampal neuroplasticity and increased posterior hippocampal gray matter volume associated with spatial navigation training ("The Knowledge"), these studies did not evaluate disease immunity. Furthermore, epidemiological and clinical data show that taxi drivers can and do develop and die from Alzheimer's disease (e.g., a population-based study of US mortality data found 171 Alzheimer's deaths among 16,658 taxi drivers, and published case studies document Alzheimer's disease in former taxi drivers).
- contradicts: "Where to?" remote memory for spatial relations and landmark identity in former taxi drive… (Journal of cognitive neuroscience 2005) · cited 102x in the literature
"In this study, we present a patient, S. B., who was diagnosed with probable Alzheimer's disease long after retiring from his 40 years as a taxi driver in downtown Toronto" (abstract, background/results, passage verified)
pubmedfull study (doi) - context: London taxi drivers: A review of neurocognitive studies and an exploration of how they bui… (Hippocampus 2022) · cited 51x in the literature
"Licensed London taxi drivers have been found to show changes in the gray matter density of their hippocampus over the course of training and decades of navigation in London (UK). This has been linked to their learning and using of the "Knowledge of London," the names and layout of over 26,000 streets and thousands of points of interest in London." (abstract, background, passage verified)
pubmedfull study (doi) - contradicts: Alzheimer's disease mortality among taxi and ambulance drivers: population based cross sec… (BMJ (Clinical research ed.) 2024) · cited 20x in the literature
"Among taxi drivers, 1.03% (171/16 658) died from Alzheimer's disease, while among ambulance drivers, the rate was 0.74% (10/1348)." (abstract, results)
pubmedfull study (doi)
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.